Related Experiment Video
Updated: Jan 15, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
EP300 compromises antitumor immunity by increasing SOCS1 expression
Yanqiong Zeng1, Ying Zhou1,2, Jiayin Ruan1
1National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
Background:
Beyond supporting cancer cell proliferation, tumor growth relies on the ability of cancer cells to evade immune surveillance. Identifying novel molecules that promote tumor immune escape may help develop more effective immunotherapeutic strategies. The histone acetyltransferase E1A-binding protein p300 (EP300) is a key epigenetic regulator that modulates gene transcription through chromatin remodeling and acetylation of histones and transcription factors. However, its role in regulating immune evasion remains incompletely understood. This study investigates the impact of EP300 on tumor immune escape and suggests its potential as an immunotherapeutic target.
Methods:
We analyzed tissue microarrays from patients with lung adenocarcinoma using immunohistochemistry to compare EP300 expression between cancerous tissues and benign tissues. Ep300-knockout cancer cells were generated using CRISPR-Cas9. Animal models were employed to assess the effect of Ep300 depletion on tumor progression and intratumoral CD8+ T cell infiltration. RNA sequencing, chromatin immunoprecipitation sequencing, flow cytometry, and western blot were used to explore the mechanism by which EP300 regulates antigen-presenting gene expression.
Results:
EP300 was significantly upregulated in cancerous tissues compared with benign tissues. Genetic ablation of Ep300 in cancer cells markedly suppressed tumor growth in vivo and enhanced CD8+ T-cell infiltration. Mechanistically, EP300 upregulates suppressor of cytokine signaling 1 (SOCS1) expression, thereby inhibiting signal transducer and activator of transcription 1 phosphorylation. This leads to downregulation of antigen-presenting genes, enabling cancer cells to evade immune surveillance by CD8+ T cells.
Conclusions:
EP300 facilitates tumor immune evasion by suppressing antigen-presenting gene expression via SOCS1 upregulation. Our findings reveal a novel role for EP300 in mediating immune escape and propose a potential therapeutic strategy to enhance antitumor immunity.
Related Concept Videos
Abnormal Proliferation
Tumor Immunotherapy
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

